For instance, the molecular targeted drugs and immune checkpoint inhibitors that target mutation, such as BRAF and NRAS gene, are effective for SSM, but ALM has a poor response to these treatments because there are relatively few above-mentioned genetic mutations [14,15,16,17]. This evidence concerns the gene NRAS and superficial spreading melanoma.